Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medicaid | 17 | 2025 | 362 | 3.590 |
Why?
|
| Nursing Homes | 13 | 2025 | 672 | 3.480 |
Why?
|
| Atrial Fibrillation | 8 | 2025 | 854 | 2.860 |
Why?
|
| Anticoagulants | 10 | 2025 | 511 | 2.830 |
Why?
|
| Accountable Care Organizations | 9 | 2025 | 67 | 2.550 |
Why?
|
| Homes for the Aged | 3 | 2025 | 161 | 1.940 |
Why?
|
| Medicare | 11 | 2025 | 611 | 1.730 |
Why?
|
| United States | 35 | 2025 | 7923 | 1.580 |
Why?
|
| Dementia | 3 | 2025 | 263 | 1.510 |
Why?
|
| Stroke | 5 | 2023 | 1196 | 1.450 |
Why?
|
| Ambulatory Care | 2 | 2025 | 317 | 1.280 |
Why?
|
| Hospice Care | 3 | 2025 | 70 | 1.180 |
Why?
|
| Food Assistance | 2 | 2025 | 21 | 1.110 |
Why?
|
| Cross-Sectional Studies | 16 | 2025 | 2616 | 1.080 |
Why?
|
| Hospices | 3 | 2025 | 39 | 1.060 |
Why?
|
| Aged | 26 | 2026 | 14648 | 1.060 |
Why?
|
| Hospitalization | 7 | 2025 | 1368 | 1.050 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 749 | 1.020 |
Why?
|
| Memantine | 2 | 2024 | 22 | 1.010 |
Why?
|
| Warfarin | 3 | 2025 | 122 | 0.920 |
Why?
|
| Atrial Flutter | 1 | 2025 | 27 | 0.920 |
Why?
|
| Aged, 80 and over | 17 | 2025 | 5520 | 0.910 |
Why?
|
| Nootropic Agents | 1 | 2025 | 13 | 0.910 |
Why?
|
| Patient-Centered Care | 3 | 2021 | 260 | 0.910 |
Why?
|
| Nutritional Support | 1 | 2025 | 12 | 0.900 |
Why?
|
| Humans | 55 | 2026 | 64243 | 0.870 |
Why?
|
| Psychotropic Drugs | 1 | 2025 | 82 | 0.860 |
Why?
|
| Skilled Nursing Facilities | 3 | 2023 | 81 | 0.840 |
Why?
|
| Potentially Inappropriate Medication List | 2 | 2021 | 15 | 0.810 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2023 | 41 | 0.790 |
Why?
|
| Inappropriate Prescribing | 2 | 2021 | 68 | 0.770 |
Why?
|
| Factor Xa Inhibitors | 2 | 2020 | 37 | 0.740 |
Why?
|
| Massachusetts | 10 | 2025 | 2094 | 0.730 |
Why?
|
| Emergency Service, Hospital | 4 | 2025 | 1118 | 0.710 |
Why?
|
| Male | 29 | 2026 | 30295 | 0.690 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2020 | 708 | 0.690 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 374 | 0.680 |
Why?
|
| Medicare Part C | 1 | 2021 | 13 | 0.670 |
Why?
|
| Female | 29 | 2026 | 33351 | 0.670 |
Why?
|
| Administration, Oral | 4 | 2024 | 374 | 0.670 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2022 | 134 | 0.660 |
Why?
|
| Antipsychotic Agents | 4 | 2024 | 304 | 0.590 |
Why?
|
| Rivaroxaban | 1 | 2018 | 19 | 0.580 |
Why?
|
| Health Equity | 3 | 2025 | 48 | 0.580 |
Why?
|
| Dabigatran | 1 | 2018 | 20 | 0.580 |
Why?
|
| Activities of Daily Living | 1 | 2020 | 293 | 0.580 |
Why?
|
| Italy | 6 | 2021 | 68 | 0.560 |
Why?
|
| Brain Ischemia | 2 | 2019 | 421 | 0.560 |
Why?
|
| Metformin | 1 | 2019 | 74 | 0.550 |
Why?
|
| Subacute Care | 1 | 2017 | 9 | 0.540 |
Why?
|
| Rehabilitation Centers | 1 | 2017 | 12 | 0.540 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 167 | 0.530 |
Why?
|
| Stroke Rehabilitation | 1 | 2017 | 50 | 0.510 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 221 | 0.500 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2021 | 489 | 0.470 |
Why?
|
| Cohort Studies | 5 | 2024 | 2604 | 0.470 |
Why?
|
| General Practitioners | 1 | 2015 | 15 | 0.460 |
Why?
|
| Hemorrhage | 3 | 2024 | 274 | 0.450 |
Why?
|
| Drug Utilization | 3 | 2021 | 208 | 0.440 |
Why?
|
| Deprescriptions | 2 | 2025 | 28 | 0.430 |
Why?
|
| Nurses | 1 | 2015 | 109 | 0.420 |
Why?
|
| Cholinesterase Inhibitors | 2 | 2024 | 46 | 0.410 |
Why?
|
| Health Care Costs | 3 | 2025 | 215 | 0.410 |
Why?
|
| Middle Aged | 14 | 2026 | 17899 | 0.400 |
Why?
|
| Retrospective Studies | 7 | 2024 | 6726 | 0.400 |
Why?
|
| Cost of Illness | 1 | 2014 | 169 | 0.390 |
Why?
|
| Biopsy | 1 | 2014 | 447 | 0.380 |
Why?
|
| Proportional Hazards Models | 6 | 2022 | 735 | 0.380 |
Why?
|
| Managed Care Programs | 2 | 2025 | 89 | 0.380 |
Why?
|
| Patient Care Team | 1 | 2015 | 340 | 0.380 |
Why?
|
| Mammography | 1 | 2014 | 290 | 0.360 |
Why?
|
| Health Care Surveys | 2 | 2025 | 289 | 0.350 |
Why?
|
| Drug Prescriptions | 2 | 2025 | 170 | 0.350 |
Why?
|
| Treatment Outcome | 6 | 2024 | 5691 | 0.350 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 321 | 0.340 |
Why?
|
| Adult | 11 | 2026 | 17117 | 0.340 |
Why?
|
| Fee-for-Service Plans | 2 | 2021 | 68 | 0.330 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 620 | 0.330 |
Why?
|
| Primary Health Care | 3 | 2025 | 711 | 0.320 |
Why?
|
| Quality of Life | 1 | 2017 | 1257 | 0.320 |
Why?
|
| Bipolar Disorder | 2 | 2022 | 247 | 0.310 |
Why?
|
| Mass Screening | 1 | 2014 | 693 | 0.290 |
Why?
|
| Health Services Accessibility | 2 | 2025 | 575 | 0.290 |
Why?
|
| Qualitative Research | 4 | 2026 | 728 | 0.280 |
Why?
|
| Drug Monitoring | 2 | 2022 | 206 | 0.280 |
Why?
|
| Cognition Disorders | 2 | 2021 | 218 | 0.280 |
Why?
|
| Sex Factors | 3 | 2021 | 979 | 0.270 |
Why?
|
| Medicare Part D | 2 | 2025 | 36 | 0.260 |
Why?
|
| Socioeconomic Factors | 3 | 2022 | 788 | 0.250 |
Why?
|
| Age Factors | 3 | 2021 | 1569 | 0.240 |
Why?
|
| Child | 4 | 2025 | 4583 | 0.240 |
Why?
|
| Meals | 1 | 2026 | 23 | 0.240 |
Why?
|
| Food Services | 1 | 2026 | 27 | 0.240 |
Why?
|
| Pharmacoepidemiology | 1 | 2025 | 8 | 0.240 |
Why?
|
| Observational Studies as Topic | 1 | 2025 | 63 | 0.230 |
Why?
|
| Breast Neoplasms | 1 | 2014 | 1211 | 0.230 |
Why?
|
| Time Factors | 3 | 2019 | 3724 | 0.230 |
Why?
|
| Patient Compliance | 2 | 2026 | 362 | 0.230 |
Why?
|
| Social Determinants of Health | 3 | 2022 | 141 | 0.230 |
Why?
|
| Health Care Reform | 2 | 2023 | 88 | 0.230 |
Why?
|
| Diet Therapy | 1 | 2025 | 15 | 0.230 |
Why?
|
| Residence Characteristics | 3 | 2023 | 221 | 0.220 |
Why?
|
| Research Design | 2 | 2025 | 583 | 0.220 |
Why?
|
| Nurse Administrators | 1 | 2024 | 18 | 0.220 |
Why?
|
| Prescription Drugs | 1 | 2025 | 51 | 0.220 |
Why?
|
| Comparative Effectiveness Research | 1 | 2024 | 46 | 0.210 |
Why?
|
| Fibrinolytic Agents | 1 | 2025 | 173 | 0.210 |
Why?
|
| Naphthalenesulfonates | 1 | 2023 | 3 | 0.210 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 2737 | 0.210 |
Why?
|
| Prescriptions | 1 | 2023 | 33 | 0.200 |
Why?
|
| Comorbidity | 3 | 2021 | 1118 | 0.190 |
Why?
|
| Social Responsibility | 1 | 2022 | 12 | 0.190 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2023 | 96 | 0.190 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 698 | 0.190 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1272 | 0.190 |
Why?
|
| Pediatrics | 1 | 2024 | 261 | 0.180 |
Why?
|
| Racism | 1 | 2023 | 88 | 0.180 |
Why?
|
| Chronic Disease | 1 | 2025 | 756 | 0.180 |
Why?
|
| Life Expectancy | 1 | 2021 | 33 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 771 | 0.180 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 65 | 0.180 |
Why?
|
| Risk Factors | 2 | 2023 | 5339 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 143 | 0.170 |
Why?
|
| Drug Repositioning | 1 | 2021 | 9 | 0.170 |
Why?
|
| Young Adult | 5 | 2025 | 4776 | 0.160 |
Why?
|
| Quality Indicators, Health Care | 2 | 2021 | 335 | 0.160 |
Why?
|
| Cognition | 1 | 2023 | 491 | 0.150 |
Why?
|
| Anticonvulsants | 1 | 2020 | 103 | 0.150 |
Why?
|
| Drug Substitution | 1 | 2019 | 40 | 0.150 |
Why?
|
| Epilepsy | 1 | 2020 | 110 | 0.150 |
Why?
|
| Geographic Mapping | 1 | 2018 | 8 | 0.150 |
Why?
|
| Interviews as Topic | 3 | 2026 | 539 | 0.140 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 349 | 0.140 |
Why?
|
| Intracranial Hemorrhages | 1 | 2018 | 68 | 0.140 |
Why?
|
| Motivation | 1 | 2020 | 289 | 0.140 |
Why?
|
| Thromboembolism | 1 | 2018 | 73 | 0.140 |
Why?
|
| Adolescent | 4 | 2025 | 6304 | 0.140 |
Why?
|
| Pneumococcal Vaccines | 1 | 2017 | 21 | 0.140 |
Why?
|
| Health Services Research | 1 | 2019 | 271 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2018 | 164 | 0.140 |
Why?
|
| Ischemic Attack, Transient | 1 | 2018 | 97 | 0.140 |
Why?
|
| Pneumococcal Infections | 1 | 2017 | 38 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2021 | 872 | 0.130 |
Why?
|
| Physicians | 1 | 2023 | 483 | 0.130 |
Why?
|
| Delayed-Action Preparations | 1 | 2017 | 118 | 0.130 |
Why?
|
| Calcium Channel Blockers | 1 | 2017 | 60 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2017 | 153 | 0.120 |
Why?
|
| Disability Evaluation | 1 | 2017 | 218 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 60 | 0.120 |
Why?
|
| Physician-Nurse Relations | 1 | 2015 | 26 | 0.110 |
Why?
|
| Salvage Therapy | 1 | 2015 | 75 | 0.110 |
Why?
|
| Schizophrenia | 1 | 2017 | 266 | 0.110 |
Why?
|
| Medicine | 1 | 2015 | 56 | 0.110 |
Why?
|
| Pneumonia | 1 | 2017 | 291 | 0.110 |
Why?
|
| False Positive Reactions | 1 | 2014 | 79 | 0.110 |
Why?
|
| Interprofessional Relations | 1 | 2015 | 137 | 0.110 |
Why?
|
| Acute Coronary Syndrome | 1 | 2017 | 253 | 0.100 |
Why?
|
| Length of Stay | 1 | 2017 | 818 | 0.100 |
Why?
|
| Insurance Coverage | 1 | 2014 | 99 | 0.100 |
Why?
|
| Mental Disorders | 1 | 2021 | 794 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 531 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2017 | 432 | 0.100 |
Why?
|
| Health Promotion | 1 | 2017 | 505 | 0.100 |
Why?
|
| Myocardial Infarction | 1 | 2018 | 915 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 421 | 0.090 |
Why?
|
| Insurance Claim Review | 2 | 2022 | 76 | 0.080 |
Why?
|
| Pharmacists | 2 | 2023 | 129 | 0.070 |
Why?
|
| Quality of Health Care | 2 | 2023 | 526 | 0.070 |
Why?
|
| Prevalence | 2 | 2025 | 1407 | 0.070 |
Why?
|
| Delphi Technique | 1 | 2025 | 102 | 0.060 |
Why?
|
| Consensus | 1 | 2025 | 185 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2025 | 233 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2024 | 203 | 0.050 |
Why?
|
| Health Policy | 1 | 2025 | 195 | 0.050 |
Why?
|
| Health Services Needs and Demand | 1 | 2024 | 214 | 0.050 |
Why?
|
| Housing | 1 | 2023 | 74 | 0.050 |
Why?
|
| Risk Adjustment | 1 | 2023 | 94 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 84 | 0.050 |
Why?
|
| Income | 1 | 2023 | 172 | 0.050 |
Why?
|
| Poverty | 1 | 2023 | 299 | 0.040 |
Why?
|
| Interinstitutional Relations | 1 | 2021 | 37 | 0.040 |
Why?
|
| Administrative Personnel | 1 | 2021 | 31 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2022 | 205 | 0.040 |
Why?
|
| Multimorbidity | 1 | 2021 | 50 | 0.040 |
Why?
|
| Palliative Care | 1 | 2023 | 239 | 0.040 |
Why?
|
| Survival Rate | 1 | 2022 | 859 | 0.040 |
Why?
|
| Cooperative Behavior | 1 | 2021 | 226 | 0.040 |
Why?
|
| Proteomics | 1 | 2021 | 294 | 0.040 |
Why?
|
| Quality Improvement | 1 | 2023 | 455 | 0.040 |
Why?
|
| Communication | 1 | 2023 | 587 | 0.030 |
Why?
|
| Senior Centers | 1 | 2017 | 1 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 379 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 368 | 0.030 |
Why?
|
| Injections | 1 | 2017 | 82 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 102 | 0.030 |
Why?
|
| Taiwan | 1 | 2017 | 13 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 299 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 885 | 0.030 |
Why?
|
| Health Resources | 1 | 2017 | 94 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 407 | 0.030 |
Why?
|
| Bias | 1 | 2017 | 114 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 423 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 167 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 676 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 161 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 869 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 930 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1383 | 0.030 |
Why?
|
| Vaccination | 1 | 2017 | 371 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2015 | 99 | 0.030 |
Why?
|
| Inpatients | 1 | 2017 | 303 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 856 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 744 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 1176 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 2478 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2046 | 0.020 |
Why?
|